What is Candida auris. How does it spread. Why is it concerning. Who is at risk. How is it diagnosed. What treatments are available. How can it be prevented.

What is Candida auris and Why is it Dangerous?

Candida auris is a type of yeast that can cause severe infections in hospitalized patients. First identified in Japan in 2009, this emerging pathogen has since been reported in over 30 countries worldwide. C. auris poses a significant threat due to its ability to enter the bloodstream and spread throughout the body, potentially leading to life-threatening invasive infections.

The Centers for Disease Control and Prevention (CDC) has expressed concern about C. auris for three primary reasons:

• Multidrug resistance: C. auris is often resistant to multiple antifungal drugs commonly used to treat Candida infections, making treatment challenging.
• Difficult identification: Standard laboratory methods struggle to accurately identify C. auris, potentially leading to misidentification and inappropriate management.
• Outbreak potential: C. auris has caused outbreaks in healthcare settings, necessitating rapid identification and special precautions to prevent its spread.

How Does Candida auris Spread and Who is at Risk?

C. auris can spread through contact with contaminated surfaces or equipment, as well as from person to person. Those at highest risk for C. auris infection include:

• Patients who have recently spent time in nursing homes
• Individuals with invasive medical devices (e.g., breathing tubes, feeding tubes, central venous catheters)
• People with recent surgery
• Diabetics
• Patients who have used broad-spectrum antibiotics or antifungals

Infections have been found in patients of all ages, from preterm infants to the elderly. However, more research is needed to fully understand the risk factors associated with C. auris infections.

What Types of Infections Can Candida auris Cause?

Candida auris can cause a variety of serious infections throughout the body, including:

• Bloodstream infections
• Wound infections
• Ear infections

C. auris has also been isolated from respiratory and urine specimens, although it remains unclear whether it directly causes infections in the lungs or bladder. The severity of these infections, combined with the organism’s resistance to treatment, makes C. auris a significant concern for healthcare providers and patients alike.

How is Candida auris Diagnosed and Why is it Challenging?

Diagnosing Candida auris infections presents unique challenges due to the organism’s elusive nature. While C. auris infections are typically diagnosed through culture of blood or other body fluids, similar to other Candida infections, identifying C. auris specifically requires specialized laboratory techniques.

Why is C. auris particularly difficult to diagnose? The organism can be easily confused with other types of yeasts, especially Candida haemulonii, when using conventional laboratory methods. This misidentification can lead to inappropriate treatment and management, potentially allowing the infection to worsen or spread.

To accurately identify C. auris, laboratories must employ advanced diagnostic tools and techniques. Healthcare facilities without access to these specialized methods may struggle to properly identify and respond to C. auris infections, highlighting the importance of increased awareness and improved diagnostic capabilities in combating this emerging threat.

Treatment Challenges: Navigating Antifungal Resistance in Candida auris

One of the most concerning aspects of Candida auris is its frequent resistance to multiple antifungal drugs commonly used to treat Candida infections. This multidrug resistance poses significant challenges for healthcare providers attempting to treat infected patients.

Why is antifungal resistance in C. auris so problematic? When an organism is resistant to first-line treatments, healthcare providers must resort to alternative, often less effective or more toxic medications. In some cases, there may be very few or no effective treatment options available, potentially leading to severe outcomes for infected patients.

To address this challenge, researchers and healthcare professionals are exploring several strategies:

• Developing new antifungal agents specifically targeting C. auris
• Investigating combination therapies using existing antifungal drugs
• Exploring alternative treatment approaches, such as immunotherapy
• Implementing strict infection control measures to prevent the spread of resistant strains

As the medical community continues to grapple with antifungal resistance in C. auris, early detection and appropriate infection control measures remain crucial in managing this emerging threat.

The Global Spread of Candida auris: Tracing Its Origins and Evolution

Since its initial identification in Japan in 2009, Candida auris has rapidly emerged as a global health concern. How did this relatively new pathogen spread so quickly across the world? Researchers have been working diligently to unravel the mystery of C. auris’s origins and global dissemination.

Through retrospective analysis of Candida strain collections, scientists discovered that the earliest known strain of C. auris dates back to 1996 in South Korea. This finding suggests that the organism may have been present for years before it was officially recognized as a distinct species.

To better understand the global spread of C. auris, the CDC conducted whole genome sequencing of specimens from various regions, including:

• Eastern Asia
• Southern Asia
• Southern Africa
• South America

Whole genome sequencing produces detailed DNA fingerprints of organisms, allowing researchers to track the evolution and spread of different strains. This analysis has revealed that distinct clades of C. auris have emerged in different geographic regions, suggesting that the organism may have evolved independently in multiple locations rather than spreading from a single point of origin.

Despite being reported in over 30 countries, the true global prevalence of C. auris remains unclear. Many countries lack the specialized laboratory methods required to accurately identify the organism, meaning that infections may be occurring undetected in various parts of the world.

Preventing the Spread of Candida auris in Healthcare Settings

Given the challenges associated with treating Candida auris infections and its potential for causing outbreaks, prevention is crucial in managing this emerging threat. Healthcare facilities play a vital role in controlling the spread of C. auris and protecting vulnerable patients.

What steps can healthcare facilities take to prevent C. auris transmission? The CDC recommends a multifaceted approach:

1. Rapid identification: Implement protocols for quickly identifying C. auris in hospitalized patients.
2. Isolation precautions: Place infected or colonized patients in single rooms and use contact precautions.
3. Hand hygiene: Enforce strict hand hygiene protocols among healthcare workers and visitors.
4. Environmental cleaning: Use EPA-registered hospital-grade disinfectants effective against C. auris to clean patient rooms and equipment.
5. Screening: Consider screening patients who have had overnight stays in healthcare facilities in countries with documented C. auris transmission.
6. Communication: Notify receiving healthcare facilities when transferring a patient with C. auris.
7. Education: Provide ongoing education and training for healthcare personnel on C. auris prevention and control.

By implementing these measures, healthcare facilities can significantly reduce the risk of C. auris transmission and protect their patients from this dangerous pathogen.

The Future of Candida auris Research: Emerging Trends and Priorities

As Candida auris continues to pose a significant global health threat, researchers are focusing on several key areas to better understand and combat this emerging pathogen. What are the current priorities in C. auris research?

Improving Diagnostic Methods

Developing faster, more accurate, and more accessible diagnostic tools is crucial for early detection and appropriate management of C. auris infections. Researchers are exploring novel molecular techniques and point-of-care tests to enhance diagnostic capabilities, particularly in resource-limited settings.

Understanding Antifungal Resistance Mechanisms

Unraveling the genetic and molecular mechanisms underlying C. auris’s multidrug resistance is a top priority. This knowledge could lead to the development of new antifungal agents or strategies to overcome resistance.

Investigating Transmission Dynamics

Further research into how C. auris spreads within healthcare settings and the community is essential for developing more effective prevention strategies. This includes studying the organism’s ability to persist on surfaces and its potential for environmental reservoirs.

Exploring Host-Pathogen Interactions

Understanding how C. auris interacts with the human immune system could provide insights into why certain individuals are more susceptible to infection and potentially lead to new therapeutic approaches.

Developing Novel Therapeutics

Given the limited treatment options for multidrug-resistant C. auris infections, researchers are actively exploring new antifungal agents, combination therapies, and alternative approaches such as immunomodulatory treatments.

Enhancing Surveillance and Epidemiology

Improving global surveillance systems and epidemiological studies will help track the spread of C. auris and identify emerging strains or resistance patterns.

As research in these areas progresses, the scientific and medical communities hope to gain a better understanding of Candida auris and develop more effective strategies for prevention, diagnosis, and treatment of this formidable pathogen.

Candida auris in the Context of Global Antimicrobial Resistance

The emergence of Candida auris as a multidrug-resistant pathogen is part of a broader global concern: the rise of antimicrobial resistance (AMR). How does C. auris fit into this larger picture, and what implications does it have for public health?

Antimicrobial resistance, including antifungal resistance, is considered one of the greatest threats to global health by the World Health Organization. The ability of microorganisms like C. auris to evolve and develop resistance to multiple drugs poses significant challenges for healthcare systems worldwide.

C. auris serves as a stark example of the potential consequences of AMR:

• Limited treatment options: As C. auris becomes resistant to more antifungal drugs, healthcare providers are left with fewer effective treatment choices.
• Increased healthcare costs: Managing multidrug-resistant infections often requires longer hospital stays, more expensive medications, and additional resources.
• Higher mortality rates: Infections caused by resistant organisms like C. auris can be more difficult to treat, potentially leading to increased mortality.
• Strain on healthcare systems: Outbreaks of resistant pathogens can overwhelm healthcare facilities, particularly in resource-limited settings.

The emergence of C. auris highlights the urgent need for a coordinated global response to antimicrobial resistance. This includes:

1. Promoting responsible use of antimicrobials in both human and animal health
2. Investing in research and development of new antimicrobial agents
3. Improving global surveillance systems to track resistant organisms
4. Enhancing infection prevention and control measures in healthcare settings
5. Raising public awareness about the importance of antimicrobial stewardship

By addressing C. auris and other multidrug-resistant organisms as part of a comprehensive approach to combating antimicrobial resistance, the global health community can work towards preserving the effectiveness of life-saving antimicrobial drugs for future generations.

The Role of Healthcare Workers in Managing Candida auris

Healthcare workers play a crucial role in the prevention, detection, and management of Candida auris infections. Their vigilance and adherence to best practices are essential in controlling the spread of this dangerous pathogen within healthcare settings.

Education and Awareness

Healthcare workers must stay informed about C. auris, its characteristics, and the latest guidelines for its management. Ongoing education and training programs are vital to ensure that all staff members are equipped with the knowledge needed to recognize and respond to potential C. auris cases.

Infection Prevention and Control

Strict adherence to infection prevention and control measures is paramount in preventing the spread of C. auris. This includes:

• Proper hand hygiene practices
• Appropriate use of personal protective equipment (PPE)
• Thorough environmental cleaning and disinfection
• Implementing contact precautions for infected or colonized patients

Surveillance and Reporting

Healthcare workers should be vigilant in identifying potential C. auris cases and promptly report suspected infections to the appropriate authorities. This includes being aware of risk factors and clinical presentations associated with C. auris infections.

Patient Care and Communication

When caring for patients with C. auris infections, healthcare workers must balance effective treatment with appropriate infection control measures. Clear communication with patients and their families about the nature of the infection and necessary precautions is essential.

Interdisciplinary Collaboration

Managing C. auris infections often requires a team approach. Healthcare workers should collaborate closely with infection control specialists, laboratory personnel, and other members of the healthcare team to ensure comprehensive and coordinated care.

By fulfilling these roles effectively, healthcare workers serve as the front line of defense against the spread of Candida auris and play a critical part in protecting patient safety and public health.

Candida auris and Vulnerable Populations: Addressing Health Disparities

While Candida auris poses a threat to all individuals in healthcare settings, certain populations may be particularly vulnerable to infection or face greater challenges in receiving appropriate care. How does C. auris impact different populations, and what steps can be taken to address potential health disparities?

Identifying Vulnerable Groups

Several factors may contribute to increased vulnerability to C. auris infections:

• Age: Both very young (preterm infants) and elderly individuals may be at higher risk due to underdeveloped or weakened immune systems.
• Underlying health conditions: People with diabetes, chronic diseases, or compromised immune systems face greater risk.
• Socioeconomic status: Individuals with limited access to healthcare may experience delays in diagnosis and treatment.
• Geographic location: People in areas with limited healthcare resources or high prevalence of C. auris may be more vulnerable.

Challenges in Care Delivery

Vulnerable populations may face additional challenges in receiving appropriate care for C. auris infections:

• Limited access to specialized diagnostic tools
• Shortages of effective antifungal medications
• Inadequate infection control measures in some healthcare settings
• Language or cultural barriers affecting communication about the infection and necessary precautions

Addressing Health Disparities

To ensure equitable care and prevention of C. auris infections across all populations, several strategies can be implemented:

1. Targeted surveillance and screening programs in high-risk communities
2. Improving access to advanced diagnostic tools in underserved areas
3. Developing culturally appropriate education materials about C. auris prevention and management
4. Enhancing infection control measures in all healthcare settings, including long-term care facilities
5. Promoting research on C. auris impacts across diverse populations
6. Ensuring equitable access to effective antifungal treatments

By addressing these disparities and focusing on vulnerable populations, healthcare systems can work towards more comprehensive and equitable management of the C. auris threat, ultimately improving outcomes for all patients at risk of infection.

General Information about Candida auris | Candida auris | Fungal Diseases

Healthcare facilities in several countries have reported that a type of yeast called Candida auris has been causing severe illness in hospitalized patients. In some patients, this yeast can enter the bloodstream and spread throughout the body, causing serious invasive infections. This yeast often does not respond to commonly used antifungal drugs, making infections difficult to treat. Patients who have been hospitalized in a healthcare facility a long time, have a central venous catheter, or other lines or tubes entering their body, or have previously received antibiotics or antifungal medications, appear to be at highest risk of infection with this yeast.

Specialized laboratory methods are needed to accurately identify C. auris. Conventional laboratory techniques could lead to misidentification and inappropriate management, making it difficult to control the spread of C. auris in healthcare settings.

Because of these factors, CDC is alerting U.S. healthcare facilities to be on the lookout for C. auris in their patients.

CDC and partners continue to work closely; click here for the latest information on Candida auris. To learn more about Candida auris, read the Q&A below and:

• Fact sheet on Candida auris – Download pdf icon[PDF – 2 Pages]
• Recommendations for Laboratorians and Health Professionals
• Information for Patients and Family Members
• Questions and Answers for Healthcare Personnel

Why is CDC concerned about

C. auris infections?

CDC is concerned about C. auris for three main reasons:

1. It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections.
2. It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate management.
3. It has caused outbreaks in healthcare settings. For this reason, it is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.

What types of infections can

C. auris cause?

C. auris has caused bloodstream infections, wound infections, and ear infections. It also has been isolated from respiratory and urine specimens, but it is unclear if it causes infections in the lung or bladder.

How is

C. auris infection diagnosed?

Like other Candida infections, C. auris infections are usually diagnosed by culture of blood or other body fluids. However, C. auris is harder to identify from cultures than other, more common types of Candida. For example, it can be confused with other types of yeasts, particularly Candida haemulonii. Special laboratory tests are needed to identify C. auris. For more information, please see the Recommendations for Laboratorians and Health Professionals.

Who is at risk for infection from

C. auris?

People who have recently spent time in nursing homes and have lines and tubes that go into their body (such as breathing tubes, feeding tubes and central venous catheters), seem to be at highest risk for C. auris infection. Limited data suggest that the risk factors for Candida auris infections are generally similar to risk factors for other types of Candida infections. These risk factors include recent surgery, diabetes, broad-spectrum antibiotic and antifungal use. Infections have been found in patients of all ages, from preterm infants to the elderly. Further study is needed to learn more about risk factors for C. auris infection.

When was

C. auris first reported?

C. auris was first identified in 2009 in Japan. Retrospective review of Candida strain collections found that the earliest known strain of C. auris dates to 1996 in South Korea. CDC considers C. auris an emerging pathogen because increasing numbers of infections have been identified in multiple countries since it was recognized.

How did

C. auris get its name?

Auris is the Latin word for ear. Despite its name, C. auris can also affect many other regions of the body and can cause invasive infections, including bloodstream infections and wound infections.

Where have

C. auris infections occurred globally?

C. auris infections have been reported from over 30 countries, including the United States. Because identification of C. auris requires specialized laboratory methods, infections likely have occurred in other countries but have not been identified or reported. Click here for a map of countries with reported cases.

How did

C. auris infection spread globally?

CDC conducted whole genome sequencing of C. auris specimens from countries in the regions of eastern Asia, southern Asia, southern Africa, and South America. Whole genome sequencing produces detailed DNA fingerprints of organisms. CDC found that isolates within each region are quite similar to one another, but are relatively different across regions. These differences suggest that C. auris has emerged independently in multiple regions at roughly the same time.

Would someone be likely to get a

C. auris infection if they travel to any of these countries?

It is unlikely that routine travel to countries with documented C. auris infections would increase the chance of someone getting sick from C. auris. Infections have occurred primarily in patients who were already in the hospital for other reasons. People who travel to these countries to seek medical care or who are hospitalized there for a long time may have an increased risk for C. auris infection. 

Have

C. auris infections occurred in the United States?

Cases of C. auris infections have been reported in the United States. As laboratories continue to look for this fungus, it is likely that more cases will be reported. Click here for a map of cases in the United States.

What should someone do if they suspect they have a

C. auris infection?

CDC recommends that anyone who believes they have any fungal infection or healthcare-associated infection see a healthcare provider.

Are

C. auris infections treatable?

Most C. auris infections are treatable with a class of antifungal drugs called echinocandins. However, some C. auris infections have been resistant to all three main classes of antifungal medications, making them more difficult to treat. In this situation, multiple classes of antifungals at high doses may be required to treat the infection. Treatment decisions should be made in consultation with a healthcare provider experienced in treating patients with fungal infections.

Can a person die from infection with

C. auris?

Yes. Invasive infections with any Candida species can be fatal. We don’t know if patients with invasive C. auris infection are more likely to die than patients with other invasive Candida infections. Based on information from a limited number of patients, 30–60% of people with C. auris infections have died. However, many of these people had other serious illnesses that also increased their risk of death.

How does

C. auris spread?

C. auris can spread in healthcare settings through contact with contaminated environmental surfaces or equipment, or from person to person. More work is needed to further understand how it spreads.

How can the spread of

C. auris be prevented?

Please see the Recommendations for Laboratorians and Health Professionals.

What is CDC doing to address

C. auris?

CDC is providing guidance for clinicians and infection control personnel. For more information, please see the Recommendations for Laboratorians and Health Professionals. CDC also is working with state and local health agencies, healthcare facilities, and clinical microbiology laboratories to ensure that laboratories are using proper methods to detect C. auris and know the limitations of certain tests for detecting C. auris.

 Top of Page

Why It Should Be Diagnosed and Treated

Without treatment, a yeast infection could become more serious. There’s a chance that it could resolve on its own, but it could also worsen.

A vaginal yeast infection (vaginal candidiasis) is a relatively common fungal infection that causes thick, white discharge along with irritation, itchiness, and swelling of the vulva and vagina.

Keep reading to learn more about the downsides of ignoring yeast infections.

If left untreated, vaginal candidiasis will most likely get worse, causing itching, redness, and inflammation in the area surrounding your vagina. This may lead to a skin infection if the inflamed area becomes cracked, or if continual scratching creates open or raw areas.

Uncommon side effects of an untreated yeast infection include:

• fatigue
• oral thrush
• gastrointestinal problems

Invasive candidiasis

Invasive candidiasis occurs when the yeast infection affects other parts of the body, such as the:

• blood
• heart
• brain
• bones
• eyes

Invasive candidiasis is usually associated with an open sore that’s exposed to a yeast infection. It isn’t typically related to vaginal yeast infections. It can cause serious health complications if not promptly treated.

Candidemia

According to the Centers for Disease Control and Prevention (CDC), candidemia is one of the most common forms of invasive candidiasis in the United States. It’s also one of the most common bloodstream infections in the country.

Yeast infections are common during pregnancy due to fluctuating hormones. If you’re pregnant and think you may have a yeast infection, see a doctor so that you can get the right diagnosis and treatment.

Topical antifungals are safe to use during pregnancy, but you won’t be able to take oral antifungal medications.

According to the Food and Drug Administration (FDA), oral fluconazole (Diflucan) taken during the first trimester of pregnancy may cause birth defects. A 2016 study also linked the use of oral fluconazole taken during pregnancy with an increased risk of miscarriage.

A mild yeast infection is expected to clear up in a few days to a week. Moderate to severe infections may take 2 to 3 weeks.

Can yeast infections go away on their own?

There’s a possibility that a yeast infection can go away on its own. The probability varies from person to person.

If you decide not to treat the infection, however, it might get worse. There’s also the possibility that you’ve misdiagnosed your condition, and what you thought was candidiasis was a more serious problem.

According to the Mayo Clinic, 75 percent of women will experience a vaginal yeast infection at some point in their lifetime.

The Department of Health and Human Services (HHS) indicates that about 5 percent of women will experience recurrent vulvovaginal candidiasis (RVVC). This is defined as four or more vaginal yeast infections in 1 year.

RVVC can occur in healthy women, but it’s more common in women with diabetes or weak immune systems from conditions such as HIV.

According to the HHS, about 66 percent of women who buy yeast infection medicine don’t actually have a yeast infection.

The symptoms may be caused by an allergic reaction or irritation due to sensitivity to tampons, soaps, powders, or perfume. Or they may have another vaginal infection, such as:

• bacterial vaginosis
• chlamydia
• gonorrhea
• trichomoniasis
• herpes

You should see a doctor if you’re not 100 percent sure that you have a yeast infection. They may diagnose you with a yeast infection, or they may discover a more serious condition.

If you’re treating what you think is a yeast infection without doctor diagnosis and it doesn’t clear up in a week or two, see a doctor. The medication you’re using may not be strong enough, or you may not have a yeast infection.

You should also visit a doctor if the infection returns in a couple of months. Having more than one yeast infection in a year could be an indication of an underlying medical condition.

Don’t put off seeing a doctor if your symptoms include:

• fever
• foul-smelling or yellow discharge
• bloody discharge
• back or stomach pain
• vomiting
• increased urination

Vaginal yeast infection should be properly diagnosed and treated. If left untreated, a yeast infection may lead to health problems, such as:

• skin infections
• fatigue
• oral thrush
• gastrointestinal problems
• invasive candidiasis

Diagnosis is a critical step, as the symptoms of a yeast infection are similar to more serious conditions, such as:

• bacterial vaginosis
• chlamydia
• gonorrhea

Doctor Myasnikov warned about the mortal danger of candidiasis

July 06, 2021
12:08

She is familiar to most women, they think they know how to recognize her, and are treated for thrush on their own. In children, it is called a jam and is also harassed with folk remedies. Meanwhile, a disease caused by a seemingly harmless fungal infection can become an insidious killer. This was discussed today in the program “About the Most Important” on the channel “Russia 1”.

Candidiasis is an infection caused by microscopic yeast-like fungi of the genus Candida. Their varieties – more than two hundred, of which 30 can cause problems in humans. Alexander Myasnikov spoke about the forms and causes of the development of pathology in the program “About the Most Important” on the channel “Russia 1”.

Half of the people have Candida in their gastrointestinal or genital tract, oral cavity, and this saprophyte does not manifest itself in any way. Until one of the triggers works – illness, stress, pregnancy, taking antibiotics. And then the fungal infection reveals itself.

Most women experience it in the urogenital form. Symptoms of vaginosis (the so-called thrush) are inflammation of the vagina, swelling, itching, pain, white discharge. At the same time, candidiasis is not classified as a sexually transmitted disease (virgins also suffer from it), and it is not required to treat a partner if he does not have symptoms.

Wearers of dentures experience constant dry mouth, children are faced with oral candidiasis, which is characterized by a white coating on the mucous membranes. In people with weakened immunity for various reasons, candidiasis can descend into the esophagus, cause pain, swallowing disorder.

However, candidiasis becomes really life-threatening in intensive care units of hospitals. There are often people with microflora, “scorched” by antibiotics, and at the same time with catheters. These devices become foci of infection. Therefore, each time the catheter is changed, its tip is cut off and sent to the laboratory for culture. Hospital candidiasis can affect the liver and kidneys. In this case, he turns into a killer, which is very difficult to deal with. The chances of dying from drugs against such candidiasis are 50 to 50.

In addition, a few years ago, Japanese scientists discovered candida aureus: it is resistant to all drugs and causes severe damage to internal organs. And if in 2016 the pathogen was found in only a few patients in Japan, now it is found in patients in more than 80 countries.

Risk factors for candidiasis

One of the main ones is diabetes and even just elevated blood glucose levels. The rest are:

– Childhood, adolescence and old age
– Strong stress
– Taking certain medications (antibiotics, estrogens, corticosteroids)
– Increased sweating due to hot weather and synthetic clothing
– Excessive use of intimate hygiene products
– Intrauterine devices
– Pregnancy
– Immunodeficiency
– Obesity
– Oncological diseases

And if candidiasis occurs four or more times a year, you can suspect a genetic predisposition to it.

Dr. Myasnikov warned women against self-treatment: the symptoms of thrush are such that it is easy to confuse it with other ailments, and studies have shown that only 11 out of 600 women have correctly diagnosed themselves. So do not rush to run to the pharmacy for candles – it is better to go to the doctor.

Even more interesting news – in our Instagram (banned in Russia) and Telegram channel @smotrim_ru .

health
Russia 1
candidiasis/thrush
society
news
medicine
Alexander Myasnikov
About health: programs and films

Scientists: thrush can cause schizophrenia and memory problems 05/04/2016

Scientists: thrush can cause schizophrenia and memory problems

Infection with the sexual or oral form of thrush may be associated with an increased chance of developing schizophrenia and manic-depressive psychosis, as well as lead to the development of memory problems.

2016-05-04T17:59

2016-05-04T17:59

2016-05-04T18:11

/html/head/meta[@name=’og:title’]/@content 90 003

/html/head/meta[@name=’og:description’]/@content

2 RIA Novosti

1

5

4. 7

96

P MIA “Russia Today”

https://xn--c1acbl2abdlkab1og.xn--p1ai/awards/

2016

RIA Novosti

1

5

4.7

96

[email protected]

7 495 645-6601

Rossiya Segodnya

https://xn--c1acbl2abdlkab1og.xn--p1ai/awards/

News

en-RU

https://ria.ru/docs/about/copyright.html

https://xn--c1acbl2abdlkab1og.xn--p1ai/

RIA Novosti

1

5

4.7

96

[email protected]

7 495 645-6601 90 Russia Today 3

96

[email protected]

7 495 645-6601

Rossiya Segodnya

https://xn--c1acbl2abdlkab1og.xn--p1ai/awards/

RIA Novosti

1

5

4.7

96

[email protected]

7 495 645-6601 90 Russia Today 0002 MOSCOW, May 4 – RIA Novosti. Infection with the sexual or oral form of thrush may be associated with an increased chance of developing schizophrenia and manic-depressive psychosis, as well as lead to the development of memory problems, say doctors who published an article in the journal npj Schizophrenia.

“Of course, it is too early to say that Candida can actually cause mental health problems, and vice versa. However, since these infections can be easily removed from the body, and therefore psychotherapists and psychiatrists should pay attention to whether their patients suffer from thrush,” said Emily Severance of John University and Hopkins in Baltimore (USA).

Severance and her colleagues uncovered this unusual connection between fungi and mental problems by studying several unusual cases of schizophrenia in which patients complained of sudden mental health problems after they contracted a particularly aggressive form of thrush.

These cases led scientists to the idea that infection with various fungi and microbes can lead to the development of a number of problems with the functioning of the brain and other components of the nervous system. They tested this hypothesis by comparing blood, microflora, and mucous membrane samples from several hundred healthy people and psychiatric patients suffering from schizophrenia or manic-depressive disorder.

Toxoplasma parasite can provoke suicide attempts – scientists

August 17, 2012, 13:58

Initially, scientists failed to establish links between Candida fungi and mental disorders, but when the authors of the article began to compare data only for men and women, the picture changed radically.

In particular, men were about twice as likely to suffer from this infection when they were schizophrenics. A similar picture, although less pronounced, was observed for carriers of manic-depressive psychosis.

Scientists: toxoplasmosis causes irreversible changes in brain function

September 19, 2013, 01:00

They forgot new information faster than other participants in the experiment who did not become infected with Candida.

Does this relationship really exist? As the authors of the article themselves believe, based on the recently discovered effects that the Toxoplasma parasite causes in the brain of humans and rodents, it really has a right to exist.